



## Caribou Biosciences to Present at Upcoming Investor Conferences

March 7, 2022

BERKELEY, Calif., March 07, 2022 (GLOBE NEWSWIRE) -- [Caribou Biosciences, Inc.](https://www.cariboubio.com) (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribou's president and chief executive officer, will present a company overview at the following upcoming investor conferences in March:

- **Oppenheimer 32<sup>nd</sup> Annual Healthcare Conference**  
Wednesday, March 16<sup>th</sup>, at 10:00 am ET
- **H.C. Wainwright Gene Therapy and Gene Editing Conference**  
Wednesday, March 30<sup>th</sup>, with a corporate overview presentation webcast available beginning at 7:00 am ET

Webcasts of the presentations will be accessible via Caribou's website on the [Events](#) page. Archived copies of the webcasts will be available on the Caribou website for 30 days after the events.

### About Caribou's Novel Next-Generation CRISPR Platform

CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Type II and Type V CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems occasionally edit unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed chRDNA (pronounced "chardonnays"), RNA-DNA hybrid guides that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.

### About Caribou Biosciences, Inc.

Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company's genome-editing platform, including its proprietary Cas12a chRDNA technology, enables superior precision to develop cell therapies that are specifically engineered for enhanced persistence. Caribou is advancing a pipeline of off-the-shelf CAR-T and CAR-NK cell therapies for the treatment of patients with hematologic malignancies and solid tumors. Follow us [@CaribouBio](#) and visit [www.cariboubio.com](http://www.cariboubio.com).

*"Caribou Biosciences" and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.*

### Caribou Biosciences, Inc.

#### Contacts:

Amy Figueroa, CFA  
Investor Relations and Corporate  
Communications  
[afigueroa@cariboubio.com](mailto:afigueroa@cariboubio.com)

#### Investors:

Elizabeth Wolffe, Ph.D., and Sylvia Wheeler  
Wheelhouse LSA  
[lwolffe@wheelhouseslsa.com](mailto:lwolffe@wheelhouseslsa.com)  
[swheeler@wheelhouseslsa.com](mailto:swheeler@wheelhouseslsa.com)

#### Media:

Greg Kelley  
Ogilvy  
[gregory.kelley@ogilvy.com](mailto:gregory.kelley@ogilvy.com)  
617-461-4023